Trial Profile

Pilot study on efficacy and tolerance of peg-interferon alpha-2a (Pegasys) added to tenofovir disoproxil fumarate and emtricitabine (Truvada) in AGHBe positive HBV (hepatitis B virus)-HIV co-infected patients.

Status: Completed

Phase of Trial: Phase II/III

Latest Information Update: 10 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Peginterferon alfa-2a (Primary) ; Emtricitabine/tenofovir disoproxil fumarate
Indications Hepatitis B; HIV-1 infections
Focus Therapeutic Use
Acronyms HB01EMVIPEG

14 Jan 2015 According to the ClinicalTrials.gov record, status changed from active, no longer recruiting to completed.
21 Feb 2012 Actual patient number (56) added as reported by ClinicalTrials.gov.
21 Feb 2012 Trial phase changed from III to II/III as reported by ClinicalTrials.gov.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com